Pabau Engage inbox

Pabau Engage is here: every patient conversation in one inbox.

Learn more
ICD-10-CM Code

ICD code L40.9 – Psoriasis, unspecified

Billable Code Specific Code


Code Definition

L40.9 is the billable ICD-10-CM code for psoriasis, unspecified. It applies when the record confirms psoriasis but names no subtype, such as plaque, guttate or pustular.

The ICD-10-CM index sends an unqualified "psoriasis" to L40.9. Once the note names a subtype, that subtype's own code applies, so plaque psoriasis or psoriasis vulgaris is L40.0.

Chapter
L00-L99 Diseases of the skin and subcutaneous tissue
Category
L40 Psoriasis
Group
L40.9 Psoriasis, unspecified
Billable
Yes
Code also known as
psoriasis NOS, psoriasis unspecified, psoriatic skin disease
Save time. Improve accuracy. Get paid faster.
Automate coding with Pabau

Let Pabau's smart automation suggest the right codes, reduce claim denials, and keep your practice compliant—effortlessly.

  • AI-powered code suggestions
  • Real-time compliance checks
  • Faster claims, fewer denials
Why practices choose Pabau
Save hours every week

Automate repetitive tasks and focus on what matters most—your patients.

Improve accuracy

Reduce coding errors and ensure compliance with the latest regulations.

Get paid faster

Clean claims, fewer denials, and faster reimbursements.

Grow with confidence

Powerful insights and reporting to help your practice thrive.

HIPAA compliant SOC 2 certified GDPR-compliant Trusted by 4,000+ clinics worldwide

Key takeaways

Key takeaways

L40.9 is the billable ICD-10-CM code for psoriasis when the encounter note confirms the diagnosis but names no subtype.

A named subtype always moves the claim to its own code, so plaque psoriasis or psoriasis vulgaris is L40.0, never L40.9.

The FY2026 tabular list puts no Excludes note on L40.9, L40.5- or the L40 category. A rejected L40.9 and L40.5- pairing comes from payer edits.

Medicare Part D plans and most commercial plans require prior authorization for biologics, and many payers ask for BSA or PASI scores.

Pabau, the practice management platform we build, submits US claims through Claim.MD and tracks prior authorization codes on the patient’s case.

ICD-10 code L40.9: Official descriptor, code structure, and billable status

ICD-10 code L40.9 is the billable diagnosis code for psoriasis, unspecified. It sits in Chapter 12 (Diseases of the skin and subcutaneous tissue), block L40-L45 (Papulosquamous disorders). The code is unchanged in CDC’s FY2027 ICD-10-CM release, which applies to services from October 1, 2026.

The table below shows the core reference facts coders need before building a claim.

FieldValue
CodeL40.9
Official descriptorPsoriasis, unspecified
ICD-10-CM systemICD-10-CM (United States)
ChapterChapter 12, Diseases of the skin and subcutaneous tissue (L00-L99)
BlockL40-L45, Papulosquamous disorders
Parent categoryL40, Psoriasis
BillableYes, valid for claims in FY2026 and FY2027
SpecificityUnspecified. Use it only when no subtype is documented

“Unspecified” does not put the diagnosis in doubt. It means the note describes psoriasis without naming its morphological subtype. When a subtype is documented, the guidelines require the more specific code.

The L40 psoriasis codes and when to use each

The L40 category has eight subcategories and 13 billable codes. L40.5- expands to six of them, one per psoriatic arthropathy pattern. L40.9 is the residual code, so it applies only when the note supports none of its more specific siblings.

CodeDescriptorUse when documentation shows…
L40.0Psoriasis vulgaris (includes plaque and nummular psoriasis)Raised, red plaques with silvery scale, with the type named
L40.1Generalized pustular psoriasisWidespread sterile pustules, such as the von Zumbusch pattern
L40.2Acrodermatitis continuaChronic pustular eruption on the fingertips or toes
L40.3Pustulosis palmaris et plantarisPalmoplantar pustulosis on the palms, the soles or both
L40.4Guttate psoriasisSmall drop-shaped lesions, often after a streptococcal infection
L40.50-L40.59Arthropathic psoriasis (six codes)Joint involvement documented, coded by joint pattern
L40.8Other psoriasisA named variant outside L40.0-L40.5-, such as flexural psoriasis
L40.9Psoriasis, unspecifiedPsoriasis confirmed, but no subtype documented in the note

Read the table as a run of questions about the note. The path ends at L40.9 only when every answer is no.

Decision flow for choosing an L40 psoriasis code: plaque, vulgaris or nummular named goes to L40.0; a pustular pattern to L40.1, L40.2 or L40.3; guttate to L40.4; another named variant such as flexural to L40.8; no subtype named ends at L40.9 Psoriasis, unspecified. Joint involvement uses L40.50 to L40.59.
Each question checks the note for a named subtype, so L40.9 is the last stop on the path. Codes and index paths come from the CDC/NCHS FY2026 and FY2027 ICD-10-CM releases.

The CDC/NCHS ICD-10-CM web tool shows the official tabular list and index for each of these codes. It includes inclusion notes and revision history by fiscal year.

Inclusion and Excludes notes for L40.9

L40.9 carries no notes of its own in the FY2026 tabular list. It has no inclusion terms and no Excludes1 or Excludes2 note. The L40 category and the L40.5 arthropathy subcategory carry none either, and the FY2027 tabular addenda add none.

  • Index path: The Alphabetic Index sends “psoriasis” with no qualifier to L40.9. Psoriasis vulgaris, plaque psoriasis and nummular psoriasis index to L40.0 instead.
  • Chapter-level Excludes2: Chapter 12 opens with an Excludes2 note listing conditions classified elsewhere. Examples include systemic connective tissue disorders (M30-M36), neoplasms (C00-D49) and viral warts (B07.-). Excludes2 means the condition is not part of L40.9, but both codes may be reported when both are present.
  • Annual check: A note can be added in any October release. Review the current tabular through CMS ICD-10 codes before you bill L40.9 alongside another L40 code.

When psoriatic arthritis is documented with skin psoriasis, pick the L40.5- code that matches the joint pattern first. Then decide whether the skin disease needs its own code, based on what the provider addressed. No tabular note forbids the pair, but payer edits can still question it.

Pro Tip

Before you send L40.9 with an L40.5- code, check the current tabular Excludes notes and the payer’s own edits. The FY2026 tabular has no note on that pair. If the payer still rejects it, report the condition the provider addressed at that visit.

What the encounter note must show to support L40.9

An unspecified code still needs specific documentation. ICD-10-CM Official Guidelines Section I.B.2 require each code to reach the highest level of specificity documented in the medical record.

To support ICD-10 code L40.9, the encounter note should contain the following:

  • Confirmed diagnosis: The note lists psoriasis as a primary or secondary diagnosis. A recognized clinical synonym that does not name a subtype (e.g. ‘psoriatic disease’) also works. A rule-out or possible diagnosis does not qualify.
  • No subtype identification: The note does not name a morphological variant (plaque, guttate, pustular, etc.) when the coder assigns L40.9. If the clinician names the type, that type’s code applies.
  • Body site and extent (recommended): Payers for biologic and phototherapy claims often ask for body surface area (BSA) as evidence of severity. BSA and PASI scores are not required for L40.9, but their absence can slow prior authorization.
  • Clinician attestation: The treating provider signs or authenticates the note. An unsigned note gives the payer grounds to deny the claim on medical necessity review.

The American Academy of Dermatology (AAD) coding resources add specialty guidance for psoriasis encounters. That includes severity scoring and treatment-stage documentation that supports medical necessity.

Payer requirements and prior authorization for psoriasis claims

Medicare, Medicaid and most commercial payers accept L40.9 for routine dermatology office visits. The picture changes when high-cost treatments enter the claim.

Biologics: Medicare Part D plans and most commercial plans require prior authorization for biologic therapy, such as adalimumab, secukinumab and ixekizumab. The request usually needs L40.9 or a more specific psoriasis code. It also needs documented failure of conventional therapy, such as topicals, phototherapy or systemic drugs. Some local coverage determinations (LCDs) list the psoriasis codes that qualify, so check the applicable LCD first. Older psoriasis claims may still carry deleted code S0162, which described efalizumab, a biologic withdrawn from the US market in 2009.

Phototherapy: CPT codes 96900, 96910, 96912 and 96913 usually pair with L40.9 on phototherapy claims. Medicare requires each phototherapy visit to meet medical necessity criteria. Some jurisdictions also ask for documented topical therapy failure before they approve a course.

Medicaid: State Medicaid programs vary widely. Biologics are often non-covered or need step therapy through preferred agents first. Verify coverage at the state plan level before you discuss costs with patients.

A missing authorization is easier to catch before the visit than after the denial. Claims management software that keeps the auth code, dates and approved sessions on the patient’s case can warn staff when a session has none. Payer LCDs change each fiscal year, so review your billing compliance requirements for psoriasis annually.

Automate claims and billing with Pabau
Pabau’s claims management checks eligibility and sends CMS-1500 claims through Claim.MD. A psoriasis claim reaches the payer with the L40.9 code the clinician recorded.

Common claim denial reasons for L40.9 and how to fix them

Denials on L40.9 claims share a small set of root causes. The table below maps each one to its fix.

Denial reasonWhat it meansCorrective action
Unspecified code rejected (CO-11 / CO-167)The payer finds the diagnosis inconsistent with, or not covered for, the billed procedureReview the note. If it documents a subtype, recode to that L40 code and rebill
Medical necessity not established (CO-50)Documentation does not justify the service level or treatment billed with L40.9Appeal with BSA, PASI score, prior treatment history and the signed note
Diagnosis/procedure mismatch (CO-11)The CPT code is not covered for L40.9 under the payer’s crosswalkCheck that payer’s CPT-to-ICD-10 crosswalk, then correct or appeal with clinical rationale
Prior authorization required (CO-15)The claim carries no valid authorization number for a service that needed oneAsk for retro-authorization where the payer allows it, and flag these services before the visit
L40.5- billed with L40.9 (CO-16 or the payer’s edit-specific code)CO-16 means the claim lacks information or has billing errors. The FY2026 tabular has no Excludes note on this pairCheck the payer’s edit and the current tabular Excludes notes. Document each condition addressed, then resubmit

Tracking denials by reason code and payer shows which of these patterns repeat, so the billing team fixes each cause once. Denial management sets out that workflow, and the medical billing denial codes reference explains each reason code.

CPT codes most commonly paired with ICD-10 code L40.9

The procedure code paired with L40.9 drives the reimbursement. These CPT and HCPCS codes are commonly billed with ICD-10 code L40.9 in dermatology, with notes on medical necessity.

CodeServiceNotes
99213 / 99214Established patient office visit (E/M)The most common pairing. The level depends on the MDM or time documented
99203 / 99204New patient office visit (E/M)The initial psoriasis evaluation. Complexity sets the level
96900Actinotherapy (ultraviolet light)Often used for narrowband UVB. L40.9 is accepted, and LCD criteria apply
96910Photochemotherapy; tar and UVB (Goeckerman) or petrolatum and UVBLess common. Document the tar or petrolatum application and the UVB exposure
96912Photochemotherapy; psoralens and UVA (PUVA)Prior authorization is commonly required. Document the treatment failure history
J0139, J3357Physician-administered biologics: J0139 (adalimumab, 1 mg), J3357 (ustekinumab)J0139 replaced J0135 on January 1, 2025. Prior authorization is usually required. Self-injected agents, such as secukinumab and ixekizumab pens, are billed through the pharmacy benefit

Tar and UVB courses have billing rules of their own, which the 96910 guide covers. For office visits, medical billing fundamentals help clinical staff document the decision-making behind each E/M level. That cuts downcoding on L40.9 claims.

L40.9 vs L40.0: Choosing between unspecified and plaque psoriasis

Plaque psoriasis is the most common subtype, and most estimates put it at over 80% of cases. That makes L40.9 and L40.0 the pair coders confuse most often.

The decision rule has two branches:

  • Use L40.0 when the note names plaque psoriasis, psoriasis vulgaris or nummular psoriasis. It also applies when the description clearly shows raised erythematous plaques with silvery scale. The standard is a named subtype, not a general impression.
  • Use L40.9 when the note documents psoriasis but does not name or clearly imply the subtype. That fits a first visit where the clinician records the working diagnosis before characterizing the pattern. It also fits a brief follow-up note that references an existing diagnosis without restating the type.

The choice changes payment on biologic claims. Some payer LCDs list specific L40 codes as qualifying diagnoses, and L40.9 may not be on that list. A claim coded L40.9 when the note supports L40.0 can then be denied for a non-qualifying diagnosis.

L40.9 and psoriatic arthritis: Coding both conditions on the same claim

Psoriatic arthritis (PsA) codes, L40.50 through L40.59, describe joint involvement in psoriatic disease. They need their own documentation. That means the joint distribution, the pattern (distal interphalangeal, mutilans, spondylitic, juvenile or other) and clinical evidence of inflammatory arthropathy.

Whether L40.9 and an L40.5- code go on the same claim depends on the reason for the visit and the payer’s edits:

  • When the visit is mainly for skin psoriasis and psoriatic arthritis is a background condition, dual coding may fit. Both conditions need attention at the visit, and the note has to reflect both.
  • When a rheumatologist manages only the joint disease at the visit, L40.5- alone is usually correct. L40.9 stays on the problem list but not necessarily on that claim.
  • The FY2026 tabular list has no Excludes note between L40.9 and L40.5-. Check the current tabular at CMS ICD-10 codes each October before you dual-code.

ICD-10-CM 2026 and 2027 updates: Has L40.9 changed?

L40.9 has not changed in the FY2026 or FY2027 ICD-10-CM release. The descriptor is still “Psoriasis, unspecified,” the code is still billable, and neither update added an Excludes note or inclusion term. The FY2027 release took effect on October 1, 2026, and no crosswalk or revalidation is needed.

The rest of the L40 category is unchanged too, at 13 codes. You can confirm this in the FY2027 addenda files listed on the CMS ICD-10 codes page. Existing claims and superbills that use L40.9 need no change.

Pro Tip

Add L40.9 to your annual code review even though it rarely changes. Codes that clinicians pick by habit cause the most trouble. A 10-minute tabular review each October catches new notes before they cause denials.

How to enter L40.9 in your EHR and practice management system

Entering ICD-10 code L40.9 correctly in the EHR keeps the code on the claim in line with the clinical note. The standard dermatology workflow has five steps.

  1. Search by code or descriptor: Enter “L40.9” or “psoriasis unspecified” in the diagnosis search field. Most EHRs list L40.9 with its siblings, so confirm you picked the unspecified code and not L40.0.
  2. Link to the encounter: Attach L40.9 to the encounter date, not just the problem list. A claim needs a date-specific diagnosis tied to the service billed.
  3. Map to the treatment plan: When a biologic or phototherapy course is ordered, link L40.9 to the treatment plan. That builds the documentation trail payers ask for during prior authorization reviews.
  4. Attach to the invoice: The diagnosis on the invoice must match the encounter note. Pulling the code straight from the signed note avoids the transcription errors behind CO-11 mismatches.
  5. Flag for prior authorization: If the treatment needs pre-approval, the billing team should know before the patient leaves. Manual flags work, but automated warnings are more reliable for biologic orders with narrow authorization windows.

Checking the diagnosis-procedure pairing before submission is what gets you a clean claim on the first pass.

How Pabau keeps L40.9 claims in step with the note

In many dermatology practices, the diagnosis travels by hand. The clinician writes psoriasis in the note, and the billing team picks a code days later. A plaque description can then become L40.9 on the claim, or a biologic session can run without an authorization on file.

Pabau records the visit, the diagnosis and the insurance case in one patient record. US claims go out as CMS-1500 claims through Claim.MD, with eligibility checks and ERA remittances handled in the same place.

Prior authorization sits on the case too. Staff record the auth code, its dates and the approved sessions, and Pabau warns them when one is missing. So the team spots a missing authorization before the patient sits down for phototherapy or a biologic dose.

Keep psoriasis claims matched to the note

Pabau keeps the diagnosis, the authorization and the claim in one patient record. US claims go through Claim.MD, so your billing team spends less time on rework.

Pabau dashboard for dermatology billing

Conclusion

Treat L40.9 as the code for a note that names no subtype, not as the default for psoriasis. A well-documented psoriasis chart will carry L40.0 or another specific code far more often.

The biggest payoff comes before the claim is built. Ask clinicians to name the subtype when they see it, and check biologic orders for an authorization before the visit. Those two habits head off the denial patterns in the table above.

Book a demo to see how Pabau keeps psoriasis diagnoses, authorizations and claims in one record for your dermatology practice.

Continue your research

Continue your research

Need to track denial patterns across your dermatology claims? Denial management in healthcare covers how to categorize and address recurring denial reason codes before they compound into revenue loss.

Submitting claims electronically for the first time? Claim.MD clearinghouse overview explains how the clearinghouse validates claims, routes 837P files and returns ERAs for psoriasis and other dermatology claims.

Screening a patient before a biologic starts? HCPCS code M1003 covers how to bill TB screening before biologic therapy.

Frequently asked questions

What does ICD-10 code L40.9 mean?

ICD-10 code L40.9 is the billable diagnosis code for psoriasis, unspecified. It means psoriasis is clinically confirmed, but the note names no subtype such as plaque, guttate or pustular. It sits at the end of the L40 category in Chapter 12 and is valid, unchanged, in FY2026 and FY2027.

When should I use L40.9 instead of a more specific psoriasis code?

Use L40.9 only when the note confirms psoriasis but does not name or clearly describe the subtype. If the note documents plaque psoriasis, use L40.0. If it documents guttate psoriasis, use L40.4. Guidelines Section I.B.2 requires the most specific code the record supports, so L40.9 is never a shortcut for an incomplete note.

What is the difference between L40.0 and L40.9?

L40.0 is psoriasis vulgaris, which includes plaque and nummular psoriasis. L40.9 is psoriasis with no subtype documented. The note alone decides between them. Plaque psoriasis accounts for over 80% of cases, so a well-documented chart should carry L40.0 far more often than L40.9.

What are the most common claim denial reasons for L40.9?

Five patterns cover most L40.9 denials. The payer may find the diagnosis inconsistent with, or not covered for, the procedure (CO-11 or CO-167). Medical necessity may be unproven without BSA or PASI documentation (CO-50). The CPT code may fall outside the payer’s crosswalk (CO-11). A biologic or phototherapy session may lack authorization (CO-15). An L40.5- code billed with L40.9 can trip a payer edit, returned as CO-16 or the payer’s edit-specific code.

Has L40.9 changed in the 2026 or 2027 ICD-10-CM update?

No. L40.9 is unchanged in the FY2026 and FY2027 ICD-10-CM releases. The descriptor is still Psoriasis, unspecified, the code is still billable, and no Excludes notes or inclusion terms were added. Confirm it each October in the addenda files on the CMS ICD-10 codes page.

Is L40.9 valid for psoriatic arthritis claims?

No. Psoriatic arthritis is coded L40.50 through L40.59, and L40.9 covers skin psoriasis only. The two can go on one claim when both conditions received attention and the note supports both. The FY2026 tabular has no Excludes note on that pair, but check the current tabular Excludes notes and payer edits before you dual-code.

Avatar photo
Maja Popovska
Content Writer

Maja is a Senior Content Writer at Pabau, where she covers everything from practice management and compliance to medical aesthetics and patient experience. Off the clock: binging true crime docuseries, baking and dreaming about travel.
×